Cover Image
市場調查報告書

腺苷酸A3受體 (ADORA3) - 開發中產品分析

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358700
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
腺苷酸A3受體 (ADORA3) - 開發中產品分析 Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 60 Pages
簡介

腺苷酸A3受體,又被稱之為ADORA3,是腺苷酸受體。腺苷酸A3受體可在心缺血的時候持續性介入心臟保護功能,是G蛋白偶聯受體 (GPCR) 。

本報告提供腺苷酸A3受體 (ADORA3)的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Can-Fite BioPharma Ltd.
  • Huons Co., Ltd.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0534TDB

Summary

Global Markets Direct's, 'Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2016', provides in depth analysis on Adenosine Receptor A3 (ADORA3) targeted pipeline therapeutics.

The report provides comprehensive information on the Adenosine Receptor A3 (ADORA3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
  • The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adenosine Receptor A3 (ADORA3) Overview
  • Therapeutics Development
    • Adenosine Receptor A3 (ADORA3) - Products under Development by Stage of Development
    • Adenosine Receptor A3 (ADORA3) - Products under Development by Therapy Area
    • Adenosine Receptor A3 (ADORA3) - Products under Development by Indication
  • Adenosine Receptor A3 (ADORA3) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Adenosine Receptor A3 (ADORA3) - Products under Development by Companies
  • Adenosine Receptor A3 (ADORA3) - Products under Development by Universities/Institutes
  • Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
    • Can-Fite BioPharma Ltd.
    • Huons Co., Ltd.
  • Adenosine Receptor A3 (ADORA3) - Drug Profiles
    • ACN-1052 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HU-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJ-1888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBF-1650 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBF-677 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piclidenoson - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Adenosine Receptor A3 (ADORA3) - Dormant Projects
  • Adenosine Receptor A3 (ADORA3) - Discontinued Products
  • Adenosine Receptor A3 (ADORA3) - Featured News & Press Releases
    • Aug 08, 2016: Can-Fites Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology
    • Jul 25, 2016: Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD
    • Jul 05, 2016: OphthaliX Announces Phase II Glaucoma Data
    • Jun 15, 2016: Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects
    • Jun 07, 2016: Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101)
    • Jun 01, 2016: Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis
    • May 02, 2016: Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association Annual Meeting
    • Apr 11, 2016: Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose
    • Mar 17, 2016: Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis
    • Jan 19, 2016: U.S. Patent & Trademark Office Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602
    • Jan 11, 2016: Can-Fite Announces Update on CF101
    • Jan 11, 2016: Can-Fite Announces Update on CF102
    • Jan 11, 2016: Can-Fite Announces Update on CF602
    • Jan 05, 2016: Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis
    • Dec 17, 2015: Can-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Pipeline by Huons Co., Ltd., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top